Mardi Dier
CIK 1574591 · EVP and CFO · last filed 2026-03-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$8.83M
Companies
7
Total Filings
77
Lifetime Open-Market Net
-$16.59M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MDGL | EVP and CFO | 13,086 | $538.80 | $7.05M | -$4.49M | 6 | 2026-03-06 |
| ORIC | Director | — | $11.91 | — | $0 | 7 | 2026-01-06 |
| PRLD | Director | 10,000 | $4.64 | $46.4K | $190.0K | 7 | 2025-06-13 |
| ACELYRIN, Inc. (SLRN) Delisted | CFO and CBO | 6,431 | $2.27 | $14.6K | $131.5K | 1 | 2023-05-11 |
| RARE | CFO & Executive Vice President | 66,695 | $25.98 | $1.73M | -$813.8K | 7 | 2022-10-17 |
| Adamas Pharmaceuticals Inc (ADMS) Delisted | Director | 10,000 | $8.22 | $82.2K | $0 | 5 | 2021-06-04 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | EVP and CFO | 10 | — | — | -$11.60M | 38 | 2020-07-02 |
Recent Filings · Page 3 of 8
77 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-10-17 | RARE | Sell (S) | −1,629 | -$65.4K | EDGAR |
| 2022-10-14 | RARE | Sell (S) | −3,484 | -$133.2K | EDGAR |
| 2022-09-19 | RARE | Grant (A) | +20,000 | $0 | EDGAR |
| 2022-06-22 | PRLD | Grant (A) | — | $0 | EDGAR |
| 2022-06-17 | ORIC | Grant (A) | — | $0 | EDGAR |
| 2022-03-03 | RARE | Mixed | +13,046 | -$62.7K | EDGAR |
| 2021-10-14 | RARE | Sell (S) | −6,738 | -$552.5K | EDGAR |
| 2021-06-22 | PRLD | Grant (A) | — | $0 | EDGAR |
| 2021-06-17 | ORIC | Grant (A) | — | $0 | EDGAR |
| 2021-06-04 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Grant (A) | +5,000 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.